Collapsible-expandable prosthetic heart valves with structures for clamping native tissue

Information

  • Patent Grant
  • 11660187
  • Patent Number
    11,660,187
  • Date Filed
    Tuesday, August 20, 2019
    5 years ago
  • Date Issued
    Tuesday, May 30, 2023
    a year ago
Abstract
A prosthetic heart valve is designed to be circumferentially collapsible for less invasive delivery into the patient. At the implant site the valve re-expands to a larger circumferential size, i.e., the size that it has for operation as a replacement for one of the patient's native heart valves. The valve includes structures that, at the implant site, extend radially outwardly to engage tissue structures above and below the native heart valve annulus. These radially outwardly extending structures clamp the native tissue between them and thereby help to anchor the prosthetic valve at the desired location in the patient.
Description
BACKGROUND OF THE INVENTION

This invention relates to prosthetic heart valves, and more particularly to prosthetic heart valves that can be collapsed to a relatively small size for delivery into a patient and then re-expanded to full operating size at the final implant site in the patient.


At present there is considerable interest in prosthetic heart valves that can be collapsed to a relatively small circumferential (or annular perimeter) size for delivery into a patient (e.g., through tubular delivery apparatus like a catheter, a trocar, laparoscopic instrumentation, or the like). This is of interest because it can help to make replacement of a patient's defective heart valve less invasive for the patient. When the prosthetic valve reaches the desired implant site in the patient, the valve is re-expanded to a larger circumferential (or annular perimeter) size, which is the full operating size of the valve.


Because of the interest in prosthetic heart valves of the above general type, improvements to valves of this type are always being sought.


BRIEF SUMMARY OF THE INVENTION

In accordance with certain possible aspects of the invention, a prosthetic heart valve may include an annular structure that is annularly continuous and that has an annular perimeter that is changeable in length between (1) a first relatively small length suitable for delivery of the valve into a patient with reduced invasiveness, and (2) a second relatively large length suitable for use of the annular structure to engage tissue of the patient adjacent to the patient's native valve annulus and thereby implant the valve in the patient. The valve further includes a flexible leaflet structure attached to the annular structure. The annular structure may comprise an annular array of diamond-shaped cells. Upstream apex portions of at least some of these cells may be resiliently biased to deflect radially outwardly from at least some other portions of the annular structure, and downstream apex portions of at least some of these cells may also be resiliently biased to deflect radially outwardly from at least some other portions of the annular structure. As a result, when the valve is in use in a patient, tissue of the patient adjacent to the patient's native heart valve annulus is clamped between the upstream and downstream apex portions, with the upstream apex portions engaging tissue upstream from the annulus, and with the downstream apex portions engaging tissue downstream from the annulus.


In accordance with certain other possible aspects of the invention, a prosthetic aortic heart valve may include an annular structure that is annularly continuous and that has an annular perimeter that is changeable in length between (1) a first relatively small length suitable for delivery of the valve into a patient with reduced invasiveness, and (2) a second relatively large length suitable for use of the annular structure to engage tissue of the patient adjacent to the patient's native aortic valve annulus and also downstream from ostia of the patient's coronary arteries to thereby implant the valve in the patient. The annular structure may include an annularly continuous annulus portion adapted for implanting adjacent the patient's native aortic valve annulus upstream from the ostia of the patient's coronary arteries, and an annularly continuous aortic portion adapted for implanting in the patient's aorta downstream from those ostia. The annulus portion and the aortic portion are preferably connected to one another only by a plurality of linking structures that are disposed to pass through at least a portion of the patient's valsalva sinus at locations that are spaced from the ostia of the patient's coronary arteries in a direction that extends annularly around the valsalva sinus. The valve further includes a leaflet structure that is attached to the annulus portion. The annulus portion includes first and second tissue clamping structures that are spaced from one another along an axis that passes longitudinally through the valve, each of the clamping structures being resiliently biased to extend radially outwardly from the leaflet structure, whereby, in use, tissue of the patient adjacent to the patient's native aortic valve annulus is clamped between the first and second clamping structures, with the first clamping structure engaging tissue upstream from the annulus, and with the second clamping structure engaging tissue downstream from the annulus.


In accordance with certain still other possible aspects of the invention, a prosthetic aortic heart valve includes an annular structure that is annularly continuous and that has an annular perimeter that is changeable in length between (1) a first relatively small length suitable for delivery of the valve into a patient with reduced invasiveness, and (2) a second relatively large length suitable for use of the annular structure to engage tissue of the patient adjacent to the patient's native aortic valve annulus and thereby implant the valve in the patient. The valve further includes a flexible leaflet structure attached to the annular structure. When a valve having these aspects of the invention is implanted in the patient, any non-leaflet part of the valve that is at the level of the patient's native coronary artery ostia is confined in a direction that is circumferential of the valve to areas that are adjacent to the patient's native aortic valve commissures or downstream projections of those commissures, each of said areas having an extent in the circumferential direction that is less than the distance in the circumferential direction between circumferentially adjacent ones of those areas. In addition, the annular structure includes first and second tissue clamping structures that are spaced from one another along an axis that passes longitudinally through the valve. Each of the clamping structures is resiliently biased to extend radially outwardly from the leaflet structure, whereby, in use, tissue of the patient adjacent to the patient's native aortic valve annulus is clamped between the first and second clamping structures, with the first clamping structure engaging tissue upstream from the annulus, and with the second clamping structure engaging tissue downstream from the annulus.


Further features of the invention, its nature and various advantages, will be more apparent from the accompanying drawings and the following detailed description.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is an elevational view of some components of an illustrative prosthetic valve in accordance with the invention.



FIG. 2 is a simplified schematic diagram of a representative portion of apparatus like that shown in FIG. 1 in relation to some native tissue structures of a patient in accordance with the invention.



FIG. 3 is generally similar to FIG. 2 for some other native tissue structures of a patient.



FIG. 4 is a simplified elevational view of another illustrative embodiment of apparatus in accordance with the invention. FIG. 4 shows the depicted apparatus in its collapsed/pre-expanded state, and as though cut along a vertical line and then laid out flat.



FIG. 5 is generally similar to FIG. 4 for another illustrative embodiment in accordance with the invention.



FIG. 6 is a simplified elevational view of another illustrative embodiment of apparatus in accordance with the invention.



FIG. 7 is a simplified perspective view of another illustrative embodiment of apparatus in accordance with the invention.



FIG. 8 is a simplified perspective view showing an illustrative embodiment of another component added to what is shown in FIG. 7 in accordance with the invention.



FIG. 9 is generally similar to FIG. 8, but shows an alternative embodiment with additional possible features in accordance with the invention.



FIG. 10 is generally similar to FIG. 9, but shows an illustrative embodiment of more components added to what is shown in FIG. 9 in accordance with the invention.



FIG. 11 is a simplified perspective view showing in more detail a representative portion of the components that are added in FIG. 10.



FIG. 12 is a simplified perspective view of another illustrative embodiment of apparatus in accordance with the invention.



FIG. 13 is a simplified perspective view of another illustrative embodiment of apparatus in accordance with the invention.



FIG. 14 is a simplified elevational view of still another illustrative embodiment of apparatus in accordance with the invention.



FIG. 15 is generally similar to FIG. 14, but shows an illustrative embodiment of more components added to what is shown in FIG. 14 in accordance with the invention.



FIG. 16 is a simplified elevational view of another illustrative embodiment of apparatus in accordance with the invention.



FIG. 17 is a simplified elevational view of another illustrative embodiment of apparatus in accordance with the invention.



FIG. 18 is a simplified elevational view of another illustrative embodiment of a prosthetic heart valve in accordance with the invention.



FIG. 19 is a simplified perspective view of an embodiment like that shown in FIG. 18 with other possible elements added in accordance with the invention.



FIG. 20 is a simplified elevational view of another illustrative of a prosthetic heart valve in accordance with the invention.



FIG. 21 is a simplified perspective view of another illustrative embodiment of a component for a prosthetic heart valve in accordance with the invention.



FIG. 22 is a simplified perspective view of another illustrative embodiment of a prosthetic heart valve in accordance with the invention.



FIG. 23 is a simplified perspective view of another illustrative embodiment of a prosthetic heart valve in accordance with the invention.



FIG. 24 is a simplified perspective view of another illustrative embodiment of a component for a prosthetic heart valve in accordance with the invention.



FIG. 25 is generally similar to FIG. 24 for still another illustrative embodiment of a component for a prosthetic heart valve in accordance with the invention.



FIG. 26 is a simplified elevational view of yet another illustrative embodiment of a component for a prosthetic heart valve in accordance with the invention.



FIG. 27 is a simplified perspective view of still another illustrative embodiment of a prosthetic heart valve in accordance with the invention.



FIG. 28 is a simplified cross section of a typical patient tissue structure that is useful for explaining certain principles of the invention.





DETAILED DESCRIPTION

Certain components of an illustrative embodiment of a prosthetic heart valve 10 in accordance with the invention are shown in FIG. 1. Valve 10 is designed for use as a replacement for a patient's native aortic valve. (Other valve types will be considered later in this specification.) FIG. 1 shows valve 10 in its expanded condition, i.e., the condition that the valve has when implanted in the patient. The depiction of valve 10 that is provided in FIG. 1 may omit certain components that the valve may have, but to some extent this is done to better reveal the components that are depicted in FIG. 1. More information will be provided about these possibly omitted components later in this specification. Also, FIG. 1 shows by representative arrows 42 and 44 that certain parts of the structure shown in the FIG. may deflect farther out and down (in the case of the parts associated with arrows 42) or farther out and up (in the case of the parts associated with arrows 44) than happens to be shown in FIG. 1. This will also be explained in more detail later in this specification.


Among the components of valve 10 are an annular metal structure 20/30/40, and a leaflet structure 100. Metal structure 20/30/40 forms a complete, continuous annulus around a longitudinal axis (not shown) that passes through the center of the valve. This central longitudinal axis is vertical, given the orientation of the valve shown in FIG. 1. Structure 20/30/40 can be reduced in annular size from the size shown in FIG. 1 by compressing that structure in the annular or circumferential direction. When this is done, structure 20/30/40 shrinks by partial collapse of the diamond-shaped cells 22 and 46 of aortic portion 20 and annulus portion 40. Later FIGS. will show examples of how such cells and/or other collapsible shapes can collapse or shrink in a direction that is annular of the valve. In other words, when the structure is thus made to shrink in the annular direction, the length of the perimeter measured around the outside of the valve becomes smaller. There is no significant change in the overall topological shape of the valve, especially metal structure 20/30/40, between its large and small perimeter sizes or at any time as it transitions between those sizes. For example, if the valve is approximately a circular annulus in its full (FIG. 1) size, it remains an approximately circular annulus as it is reduced to its smaller perimeter size. It is preferred that there be no folding, wrapping, overlapping, or other major topological shape change of metal structure 20/30/40 to reduce its perimeter size or to subsequently re-expand it.


The above-described changes (i.e., collapsing and re-expanding) of metal structure 20/30/40 are preferably all elastic deformations. For example, metal structure 20/30/40 can be resiliently biased to have the size and shape shown in FIG. 1. In such a case, collapsing of metal structure 20/30/40 to the above-mentioned smaller perimeter, annular, or circumferential size can be by elastic deformation of the metal structure, e.g., by confining metal structure 20/30/40 in a tube having a smaller perimeter than the full FIG. 1 size of the valve. Such a tube can be part of apparatus for delivering the valve into a patient. When the valve is pushed or pulled out of the tube, metal structure 20/30/40 automatically, elastically, re-expands to the full size shown in FIG. 1. Because such a delivery tube can be smaller than the full size of the valve, the valve can be delivered into the patient less invasively than would be possible if the valve was only capable of always remaining full size as shown in FIG. 1.


As an alternative or addition to full elastic compression and self-re-expansion, re-expansion may be at least partly assisted by other means. For example, an inflatable balloon on a catheter may be used to assist valve 10 to re-expand to its full size. Such a balloon may be temporarily positioned inside valve 10 to accomplish this. This may be done either because the elastic re-expansion is not quite strong enough to get the valve back to full size when adjacent to surrounding native tissue of the patient, because some plastic re-expansion is required to get the valve back to full size, to help ensure that the valve does in fact firmly seat in and engage the desired surrounding native tissue at the implant site, or for any other reason. For the most part it will be assumed herein that all or substantially all compression and re-expansion are elastic, but the possibility of some plastic compression and re-expansion is also contemplated as mentioned earlier in this paragraph.


We turn now to a description of the various parts of metal structure 20/30/40. Part 20 is intended for implantation in the patient's native aorta downstream from the native aortic valve location, and also downstream from the patient's native valsalva sinus. Part 20 may therefore be referred to as the aortic portion of the valve or of metal support structure 20/30/40. Portion 20 is a completely annular (continuous) structure, with the ability to annularly collapse and re-expand as described earlier in this specification. Portion 20 is made up principally of an annular array of parallelogram- or diamond-shaped cells 22, which give portion 20 the ability to annularly compress and re-expand as described.


Part 40 is intended for implantation in the patient's native aortic valve annulus. Part 40 may therefore be referred to as the annulus portion of the valve or of metal support structure 20/30/40. Part 40 is also a completely annular (continuous) structure, with the ability to annularly collapse and re-expand as described earlier in this specification. Part 40 is again made up primarily of an annular array of parallelogram- or diamond-shaped cells 46, which give portion 40 the ability to annularly compress and re-expand as described.


Part 40 also includes three commissure post members 50 that are spaced from one another (e.g., approximately equally) around the valve. Each commissure post member 50 is intended for implantation at the approximate angular or circumferential location of a respective one of the patient's native aortic valve commissures. Like the native commissures, posts 50 are structures at which adjacent ones of the three leaflets of structure 100 came together in pairs. The blood inflow edge portions (lower as viewed in FIG. 1) of each leaflet are also secured to other structure of the valve below posts 50. The blood outflow edge portions of leaflets 100 (upper as viewed in FIG. 1) are free (except for their end attachments to a respective pair of posts 50). These free edges can come together to close the valve when blood pressure downstream from the valve is greater than blood pressure upstream from the valve. When the blood pressure differential reverses, the greater upstream blood pressure pushes the free edges of the leaflets apart, thereby opening the valve to allow blood flow through it.


Leaflet structure 100 is typically made of three flexible leaflet sheets. The material of these sheets can be any known flexible leaflet material such as appropriately treated natural tissue, a flexible polymer, or the like.


Each of commissure posts 50 is preferably at least partly cantilevered up (in the blood flow direction) from remaining structure of part 40. For example, toward its blood inflow (lower) end, each of posts 50 may be attached to other structure of part 40 only near and/or below the middle of that part in the longitudinal (vertical) direction. At least the upper (blood outflow) end portion of each post 50 is therefore cantilevered from that post's lower-end-portion connections to other structure of part 40. The upper end portion of each post 50 is accordingly preferably a free end (i.e., without any metal connection to other adjacent metal structure of part 40). This has a number of advantages. One of these advantages is that it makes at least the upper portions of posts 50 at least somewhat independent of the other metal structure 20/30/40 of the device. This makes it possible for at least the upper portions of posts 50 to have properties like flexure characteristics, deflection characteristics, final location characteristics, etc., that can be optimized for the purposes that these post portions must serve, while other portions of metal structure 20/30/40 can be relatively independently optimized in these various respects for the various purposes that these other portions of structure 20/30/40 must serve. As an example of this, it may be desirable for the upper portions of posts 50 to stand relatively straight up and to have flexibility that is optimized for absorbing stress from the lateral edges of the leaflets 100 that are attached to those posts. At the same time, it may be desirable for other portions of metal structure 20/30/40 that are at the same general level along the longitudinal axis of the valve to flare radially out to various degrees. This will be described in more detail later in this specification. But just to complete the point that has been started here, it may be desired for the upper portions of cells 46 to be strong enough to hold back native leaflets and/or native leaflet remnants, and/or to deflect down onto the blood outflow surface of the native valve annulus (especially in cases in which the native leaflets have been wholly or largely removed). Similarly, it may be desirable for the members of strut structures 30 to begin to incline radially outwardly as they extend toward circumferentially larger aortic portion 20 and/or as they pass through the patient's native valsalva sinus, which is also circumferentially larger than the native valve annulus.


Clarification of a point of terminology may be appropriate here. When this specification speaks of a structure extending radially outwardly or the like, this does not necessarily mean that this structure is exactly perpendicular to a longitudinal axis extending in the blood flow direction through the valve. It may only mean that the structure has at least some component of alignment that is radial of the valve, i.e., that the structure (or a geometric projection of the structure) forms some angle with the above-mentioned longitudinal axis. In short, as a general matter, a “radially extending structure” or the like does not have to be fully or exactly radial of the above-mentioned longitudinal axis, but may instead have only some vector component that is radial of that axis.


The aortic portion 20 and the annulus portion 40 of metal structure 20/30/40 are connected to one another by what may be termed struts or strut structures 30. In the illustrative embodiment shown in FIG. 1 there are six of these struts 30. They are in three pairs, with each pair being adjacent to a respective one of the three commissure posts 50. More particularly, the two struts 30 in each pair are preferably located adjacent (and relatively close to) respective opposite sides of the associated post 50. This arrangement leaves relatively large open areas (in the circumferential direction) between the pairs of struts 30. In other words, the distance in the circumferential direction between the struts 30 in any pair of those struts is preferably less than the circumferential distance between the two circumferentially closest struts in any two different pairs of those struts. Because commissure posts 50 are angularly or rotationally aligned with the patient's native aortic valve commissures, and because struts 30 pass through the patient's native valsalva sinus relatively close to longitudinal projections of posts 50, struts 30 are thus located to pass through the valsalva sinus (typically close to or at the wall of the valsalva sinus) along paths that are circumferentially spaced from the ostia of the patient's coronary arteries. In other words, struts 30 are preferably located in the circumferential direction to pass through the valsalva sinus without any possibility of a strut obstructing the ostium of a coronary artery. (Although patient anatomy can vary in this respect, the coronary artery ostia are typically located in the valsalva sinus between the native aortic valve commissures (or between longitudinal projections of the native aortic valve commissures). See also the later discussion of FIG. 28, which discussion applies to embodiments of the kind generally illustrated by FIG. 1. In particular, in the terms later discussed in connection with FIG. 28, all material of structure 30 at the level of the coronary artery ostia should be confined to areas W as shown in FIG. 28.)


In addition to the characteristics that are mentioned above, each of struts 30 is preferably serpentine in the longitudinal direction (i.e., as one proceeds along the length of any strut 30 from annulus portion 40 to aortic portion 20, the strut deviates from a straight line, first to one side of the straight line, then to the other side of the straight line, then back to the first side, and so on). One of the benefits of this type of strut configuration is that it can increase the lateral flexibility of structure 20/30/40, especially the lateral flexibility of strut portion 30 between portions 20 and 40. Lateral flexibility means flexibility transverse to a longitudinal axis that is parallel to blood flow through the valve. Prior to and during implantation, this lateral flexibility can help the valve more easily follow curves in instrumentation that is used to deliver the valve into the patient. After implantation, this lateral flexibility can help each of portions 20 and 40 seat more concentrically in its respective portion of the patient's anatomy, which portions may not be exactly perpendicularly concentric with one single, common, central longitudinal axis.


As shown in FIG. 1, the upper end of each strut 30 may connect to the lower end (or apex) of one of the cells 22 of aortic portion 20. The lower end of each strut 30 may similarly connect to the upper end (or apex) of one of the cells 46 of annulus portion 40. It should be noted, however, that especially at the lower end of strut structure 30 there are other cells 46 of annulus portion 40 that have no struts 30 connected to their upper ends or apexes. For example, arrows 42 are shown adjacent to the upper ends of two representative ones of cells 46 of this kind. These are the cells 46 whose upper portions can be configured to deflect or project radially outwardly (as indicated by the arrows 42) for such purposes (mentioned earlier, and also in more detail later) as holding back any remaining native leaflet material and/or clamping down on the blood outflow side of the patient's native valve annulus.


From the foregoing, it will be seen that the features of valve 10 for holding the valve in place in the patient can include any or all of the following: (1) the radially outward projection of some or all of the lower portions of annulus cells 46 adjacent the blood inflow side of the native aortic valve annulus; (2) the radially outward projection of the upper portions of at least some of the upper portions of annulus cells 46 adjacent possibly remaining native aortic leaflet tissue and/or adjacent the blood outflow side of the native aortic valve annulus; (3) the general radial outward expansion of annulus portion 40 against the native valve annulus; (4) the radial outward expansion of aortic portion 20 to annularly engage the inner wall surface of the aorta downstream from the valsalva sinus; and (5) the possible engagement of the inner wall surface of the valsalva sinus by strut structures 30 passing through that sinus. Although not shown in FIG. 1, it is possible to add to any suitable portion(s) of metal structure 20/30/40 barbs that project out from other adjacent structure so that they additionally engage, dig into, and/or penetrate tissue to give the implanted valve additional means for maintaining its position in the patient.


Note also that in addition to possibly engaging possibly remaining native aortic valve leaflet tissue, valve 10 has many structures for pushing any such remaining tissue radially outwardly away from possible interference with prosthetic leaflet structure 100. These structures include the upper portions of all of cells 46 and the lower portions of all of struts 30.


There are some other possible features of valve 10 that have not yet been mentioned. One of these aspects is the provision of apertures like 52 through commissure posts 50 (and possibly other portions of metal structure 20/30/40) for facilitating the attachment (e.g., using suture material or other similar strand material) of leaflet structure 100 to the metal structure. Other layers of material such as tissue, fabric, or the like may also be attached to various parts of metal structure 20/30/40 for various purposes. These purposes may include (1) helping to prevent, reduce, or cushion contact between leaflet structure 100 and metal structure 20/30/40; (2) helping to improve sealing between the valve and the surrounding native tissue (e.g., to prevent paravalvular leakage); and (3) helping to promote tissue in-growth into the implanted valve. Limited examples of such additional layers of material are shown in FIG. 1 in the form of lower fabric skirt 110 and blood inflow edge sealing ring 120. Both of structures 110 and 120 extend annularly around the outside of the lower (blood inflow) edge of valve 10. Structures like 110 and 120 may be held to metal structure 20/30/40 by sutures or other similar strand-like material, and apertures (like 52) through the metal structure (or other features of the metal structure) may be used to provide anchoring sites for such sutures or the like. Still other possible aspects of valve 10 will be discussed in connection with later FIGS.


A possibly important feature of valves in accordance with the present invention is that they can include a structure near the blood inflow edge for clamping adjacent native tissues in a particular way. In particular, the upper and lower portions of at least some of cells 46 can both pivot toward one another from a common central location. This is illustrated schematically in FIGS. 2 and 3.



FIG. 2 shows the somewhat simpler case in which the patient's native aortic valve leaflets have been removed prior to implanting valve 10. The native tissue structures that are visible in FIG. 2 are a portion 220 of the wall of the left ventricle, a portion 210 of the aortic valve annulus, and a portion 230 of the wall of the valsalva sinus. The upper portion of a representative cell 46 from FIG. 1 is shown schematically in FIG. 2 by member 142. The lower portion of that cell is shown schematically by member 144. Members 142 and 144 can pivot toward one another about central pivot point 143. As in FIG. 1, this is again indicated by arcing arrows 42 and 44. Thus members 142 and 144 initially form a relative large, open jaw structure, the two jaws of which can be released to resiliently pivot toward one another to clamp down on any tissue within their reach. In the case of FIG. 2, this can include some of the tissue of sinus wall 230 and the upper surface of annulus 210 (for upper pivoting member 142), and some of the tissue of left ventricle wall 220 and the lower surface of annulus 210 (for lower pivoting jaw member 144). Clamping force vector component diagrams in FIG. 2 indicate the nature of the clamping forces that can result from these kinds of tissue engagement. For example, member 142 can have a radially outward clamping force component 142a and a longitudinally downward clamping force component 142b. Similarly, member 144 can have a radially outward clamping force component 144a and a longitudinally upward clamping force component 144b. Opposing clamping force components 142b and 144b tend to clamp tissue between members 142 and 144. But radially outward force components 142a and 144a also engage tissue and therefore also help to hold valve 10 in place in the patient.



FIG. 3 illustrates the somewhat more elaborate case in which native aortic leaflet tissue 240 (typically, or at least often, stenotic) remains in the vicinity of prosthetic valve 10 when the valve is implanted. FIG. 3 shows that in this type of situation upper member 142 both engages leaflet tissue 240 and helps to push it radially out of the way. Again, member 142 exerts both a radially outward force component 142a and a longitudinal (downward) force component 142b on the adjacent tissue (in this case leaflet tissue 240). The behavior and effects of lower member 144 are similar to what is shown in FIG. 2 and described earlier. Thus again the structures of valve 10 exert both radial outward tissue engaging forces 142a/144a and oppositely directed tissue clamping forces 142b/144b to hold valve 10 in place in the patient.


Recapitulating and extending the above, the attachment method of the present design applies forces in the radial and longitudinal directions to clamp onto several anatomical features, not just annulus 210. In doing this, a valve in accordance with this invention can maximize (or at least significantly increase) the orifice area at the annulus level for better blood flow. Another way of thinking about the present designs is not necessarily as “clamps,” but rather as members of a stent that conforms to the different diameters of different portions of the anatomy. Structures that only “clamp” tend to engage only both sides of the native annulus (like 210), and do not also extend to and engage other tissue structures as in the present designs. The present structures also differ from “clamp” structures that terminate from a single pointed wire. Instead, in the present designs, the conforming members are formed from continuous strut members of the base (annulus portion 40) of the stent. This can only be achieved with an annulus portion 40 that stays below the ostia of the coronary arteries and with commissure posts 50 that are “independent” of other structure of annulus portion 40 as was described earlier in this specification.


Still other features of the present valves that warrant emphasis are mentioned in the following. The annulus portion 40 of the present valves preferably expands as nearly as possible to the full size of the native valve annulus. The leaflet structure 100 is preferably mounted just inside annulus portion 40. This helps the present valves avoid any stenotic character (such as would result from having the leaflet structure or some other structure on which the leaflet structure is mounted) spaced radially inwardly from annulus portion 40. The present valves are thus ensured to have the largest opening for blood to flow through, which reduces the pressure gradient (drop) across the valve.


Note that at the level of the coronary artery ostia, the present valves have only very minimal non-leaflet structure 30; and even that minimal non-leaflet structure is rotationally positioned to pass through the valsalva sinus where it will safely bypass the coronary artery ostia. Annulus portion 40 is preferably designed to be entirely upstream (in the blood flow direction) from the coronary artery ostia. Aortic portion 20, on the other hand, is preferably designed to be entirely downstream from the coronary artery ostia (i.e., in the aorta downstream from the valsalva sinus). Some prior designs have much more extensive non-leaflet structures extending much farther into or through the valsalva sinus and therefore longitudinally beyond the coronary artery ostia. This is believed to be less desirable than the present structures.


The present valves preferably include “independent” commissure posts 50 that are “lined up” or aligned with (i.e., superimposed over) the native valve commissures. This also helps to ensure proper coronary artery flow, when combined with the fact that struts 30 are confined to being closely adjacent to posts 50 in the circumferential direction. Even relatively thin connecting members (like struts 30) could partially block a coronary artery if not correctly positioned in the circumferential direction around the valsalva sinus. But this is avoided in the present valves by the principles and features mentioned, for example, in the immediately preceding sentences.



FIG. 4 shows another illustrative embodiment of metal support structure 20/30/40. FIG. 4 shows this structure as though cut along its length and then laid flat. FIG. 4 also shows this structure in the condition that it has in its circumferentially collapsed condition. Thus, for example, the sides of what will be diamond-shaped cells 22 and 46 in the re-expanded valve are, in FIG. 4, collapsed down to being parallel with one another. Again, the fact that FIGS. like FIG. 4 show structures as though cut longitudinally and laid flat is only for ease and convenience of depiction. In actual fact these structures are complete and continuous annular structures like the structure 20/30/40 shown in FIG. 1.


Note that in the FIG. 4 design there are eyelets 24 in aortic section 20 for attachment of material and/or attachment of wires/sutures for a delivery system. On annulus section 40 the eyelets 48/52 can be used for attachment of the cuff, porcine buffer, and/or leaflets. FIG. 4 shows an annulus portion 40 with a “scalloped” inflow (lower) edge. This scalloped blood inflow edge is relatively “high” in the vicinity of the inflow end of each commissure post 50, and relatively “low” between commissure post 50 inflow ends. (“High” means more downstream; “low” means more upstream.) This can help the implanted valve avoid affecting the patient's mitral valve, which tends to be radially spaced from the aortic valve along a radius of the aortic valve that corresponds to the radial location of one of the aortic valve's commissures. Because the valves of this invention are preferably implanted with posts 50 superimposed inside the native valve commissures, this places one of the “high” portions 41 of the inflow edge adjacent the patient's mitral valve. The resulting recessing 41 of annulus portion 40 helps the prosthetic valve avoid interfering with the mitral valve.



FIG. 5 shows yet another illustrative embodiment of metal support structure 20/30/40. FIG. 5 shows this embodiment in the same general way and condition as FIG. 4 shows its embodiment. Thus, as said in connection with FIG. 4, the structure shown in FIG. 5 is actually a complete, continuous annulus, and the longitudinally cut and flattened depiction shown in FIG. 5 is only employed for simplicity and greater clarity.


The FIG. 5 embodiment again has eyelets 24 in the aortic section 20 for attachment of material and/or attachment of wires/sutures for a delivery system. Also, eyelets 48/52 on annulus section 40 can be used for attachment of the cuff, porcine buffer, and/or leaflets. As compared to the FIG. 4 design (in which connecting support struts 30 are connected to the downstream apexes of certain annulus portion cells 46), in FIG. 5 the connecting support struts 30 are connected directly to posts 50. The aortic portion 20 of the FIG. 5 embodiment also has two annular arrays of cells 22a and 22b (rather than only one annular array of such cells 22 as in the earlier embodiments). Array 22a is more downstream than array 22b, but these two arrays do overlap somewhat in the longitudinal direction by virtue of the cells in the two arrays having some intervening cell members (like representative member 23) in common.


A typical way of making any of the support structures 20/30/40 of this invention is to laser-cut them from a tube.



FIG. 6 shows another illustrative embodiment of aortic portion 20, in which the cells 22 of the mesh stent can expand against the ascending aorta. This structure may or may not be covered in tissue, polymer, and/or fabric (true for any of the embodiments shown and described herein).



FIGS. 7 and 8 show another illustrative embodiment of annulus portion 40. This mesh stent has expandable cells that press against the native valve annulus and/or leaflets (if the native leaflets remain). Upper 142 and lower 144 portions of this stent clamp down on the native annulus and/or leaflets. This stent design is symmetrical around the circumference, but it may be asymmetrical to allow anatomical conformance with the mitral valve, for example. A cuff 110 made of fabric, tissue, or polymer may fully or partially encapsulate this stent as shown, for example in FIG. 8.



FIGS. 9 and 10 show an embodiment of stent 40 that includes a set of barbs 43 on the top and/or bottom to further secure the stent in order to stop migration. A partial cuff 110 (FIG. 10) allows the barbed tips 43 to be exposed to direct tissue contact for enhanced securing. The bottom section could be asymmetrical (e.g., as in FIGS. 4 and 5) to mitigate any impingement on the mitral valve. An extra-thick, toroidal section 112 of the cuff allows extra sealing capacity to prevent paravalvular leakage.



FIG. 11 shows that toroidal section 112 of cuff 110 allows extra sealing capacity to prevent paravalvular leakage. This section could be made of extra fabric, tissue, or polymer. The chamber 114 inside section 112 can accommodate an injectable polymeric substance to aid in seating.



FIG. 12 shows another illustrative embodiment of the aortic holding portion 20. In this case portion 20 is a metallic or polymeric expandable wire form with many of the same attributes discussed with the mesh stent.



FIG. 13 shows another illustrative embodiment of annulus/leaflet holding portion 40. In this case portion 40 is a metallic or polymeric expandable wire form with many of the same attributes discussed with the mesh stent.



FIGS. 14 and 15 show an illustrative assembly of an aortic portion 20 and an annulus portion 40. In FIG. 15 a pliable or semi-rigid reinforced fabric 30 connects the aortic portion 20 and the annulus/cuff portion 40/110/112 to allow somewhat independent movement. The tissue or synthetic leaflets 100 can then be attached to connecting section 30. All of the disclosed variations allow for ample areas (like 130) for blood to flow to the coronaries.


The variation shown in FIG. 16 does not include an aortic portion 20. Instead, three independent commissure posts 50 allow for leaflet attachment (e.g., with the aid of apertures 52), while the base 40 is secured in place as described earlier. Posts 50 can be lined up with the native commissures and (by virtue of the recesses like the one identified by reference number 41) allow for an opening on the lower portion to be clear of chordae and the mitral valve. The posts 50 used to attach the leaflets may be solid or have any combination of holes, slots, and/or other apertures 52.


Note that even for an embodiment like FIG. 16, when used for an aortic valve, any non-leaflet portion of the valve (such as commissure posts 50) that extends into the coronary sinus to the level of any coronary artery ostium is confined, in the circumferential direction, to locations that are well spaced from the coronary artery ostia. This is preferably accomplished by having all such non-leaflet structure confined (in the circumferential direction) to locations or areas that are at or circumferentially near the native aortic valve commissures (or downstream projections of those commissures). The circumferential width of each of these areas in which non-leaflet structure is permitted at the level of the coronary artery ostia is preferably less than the circumferential spacing at that level between circumferentially adjacent ones of those areas. It is not a problem for moving leaflet material to extend to or even beyond the level of the coronary artery ostia because the coronary arteries can fill with blood when the valve is closed. But no non-leaflet and therefore basically non-moving part of the prosthetic valve should be allowed to occupy any location at the level of the coronary artery ostia where that non-leaflet material may interfere with blood flow into the coronary arteries.



FIG. 28 illustrates the point made in the immediately preceding paragraph (and also elsewhere in this specification). FIG. 28 shows a cross section of a typical patient's valsalva sinus 300 at the level of the coronary artery ostia. The patient's native aortic commissures (or downstream projections of those commissures) are at locations 310a-c. The coronary artery ostia typically occur in bracketed areas 320. Any non-leaflet structure of a prosthetic valve in accordance with this invention that is at the level depicted by FIG. 28 should be confined to areas W. The width of each of these areas in the circumferential direction (i.e., the dimension W) is preferably less than the distance S in the circumferential direction between any two circumferentially adjacent ones of these areas.



FIG. 17 shows another illustrative embodiment that is somewhat like the embodiments in FIGS. 1, 4, and 5 in that there is a continuous link 30 between aortic section 20 and annulus section 40. In this embodiment link structure 30 itself allows for leaflet attachment, with the lower portion of each link 30 acting like a commissure post 50. To mitigate leaflet abrasion at the attachment site in this or any other embodiment, the stent may first be covered with fabric, followed by a thin layer of buffering tissue/polymer, and finally the leaflet tissue/polymer. The stent of the valve can be partially or completely covered in one or a combination of materials (polyester, tissue, etc.) to allow for better in-growth, abrasion protection, sealing, and protection from metal leachables like nickel from nitinol.


Most of the detailed discussion thus far in this specification has related to prosthetic aortic valves. However, certain aspects of what has already been said can also be applied to making prosthetic valves for other locations in the heart. The mitral valve is another valve that frequently needs replacement, and so this discussion will now turn to possible constructions for other valves such as the mitral valve.


In the case of the mitral valve (which supplies blood from the left atrium to the left ventricle), only the native valve annulus area (possibly including what is left of the native valve leaflets) is available for anchoring the prosthetic valve in place. There is nothing comparable to the aorta for additional downstream anchoring of a prosthetic mitral valve.


Structures of the types shown in FIGS. 7-11 and 13 are suitable for use in prosthetic mitral valves. In such use, annular structure 40 may be delivered into the native mitral valve annulus in a circumferentially collapsed condition and then re-expanded to the depicted size and condition in that annulus. The apex portions 142 of cells 46 at one end of structure 40 (e.g., the blood inflow end) project resiliently out and also pivot somewhat downstream as shown, for example, in FIG. 7 and engage the patient's tissue adjacent the inflow side of the patient's native mitral valve annulus. Apex portions 144 of cells 46 at the other end of structure 40 (e.g., the blood outflow end) project resiliently out and also pivot somewhat upstream and engage the patient's tissue adjacent the outflow side of the patient's native valve annulus. The tissue of and adjacent to the mitral valve annulus is thereby clamped between tissue clamping structures 142 and 144. Barbs 43 may be added as shown in FIGS. 9 and 10 for additional tissue engagement and possible penetration to additionally help hold the valve in place in the mitral valve annulus. Other features (e.g., 110 and 120) and principles discussed earlier in connection with FIGS. 7-11 and 13 apply to the possible mitral valve use of these structures and features.


An illustrative embodiment of a more fully developed prosthetic mitral valve 210 in accordance with the invention is shown in FIG. 18. In this depiction of mitral valve 210, its blood inflow end is down, and its blood outflow end is up. (This depiction may be regarded as “upside down” as compared to its orientation in a patient who is standing upright.) Analogous to what is shown in FIG. 16, valve 210 has three commissure posts 50 that are cantilevered from annular structure 40. Flexible valve leaflets 100 are attached to these posts (and elsewhere to other structure of the valve such as annular structure 40 and/or material that is used to cover structure 40). Apertures 52 through posts 50 may be used to facilitate attachment (e.g., suturing) of the leaflets to the posts. Additional apertures 54 in posts 50 may be used as sites for or to facilitate attachment of chordae tendonae (native and/or artificial replacements) to the posts. This last point will be considered further as the discussion proceeds.


The posts 50 used to attach the leaflets can be solid or can have any combination of holes and/or slots. Three independent posts 50 (i.e., “independent” because cantilevered from annular structure 40) allow for leaflet attachment, while the base 40 is secured in place as described earlier. Also, posts 50 can be lined up with the native anatomy for better leaflet opening clear of chordae and the aortic valve. Apertures 54 can be included near the downstream free ends of posts 50 for native and/or artificial chordae attachment. To mitigate leaflet abrasion at the attachment site, the stent 40 can first be covered with fabric, followed by a thin layer of buffering tissue/polymer, and finally the leaflet 100 tissue/polymer. As is true for all embodiments herein, the stent 40 of the valve can be partially or completely covered in one or a combination of materials (polyester, tissue, etc.) to allow for better in-growth, abrasion protection, sealing, and protection from metal leachables such as nickel from nitinol. The support structure 50 for the leaflets may be continuous from the clamping stent portion 40. Alternatively, the leaflet support structure may be a separate section connected to clamping portion 40, or it may be frameless.



FIG. 19 shows an example of how artificial and/or native chordae 220 can be attached prior to, during, or after implanting prosthetic mitral valve 210. These chordae attachments are made at or near the downstream free ends of posts 50. Chordae 220 can be adjusted through cored papillary muscles and/or through a port made in the apex of the beating heart.



FIG. 20 shows an alternative embodiment of prosthetic mitral valve 210 in which chordae 230 can be attached to an extended free edge 102 of the leaflets prior to, during, or after implanting of the valve in the patient. Once again, chordae 230 can be adjusted through cored papillary muscles and/or through a port made in the apex of the beating heart. The redundant coaptation portions 102 of the leaflets can be reinforced tissue (e.g., a double layer or thicker tissue), or if the leaflet is a polymer, it can be reinforced by greater thickness and/or fibers.



FIG. 21 shows that the stent 40 design can include apertures 48 around the center portion of the stent to allow for cuff, leaflet, and chordae attachment around the circumference of the stent. FIG. 22 shows that the edge of cuff 110 can follow the edge shape of stent 40 to allow for passage of chordae and reduction of interference of other anatomy, while also allowing greater flexibility of annular structure 40. FIG. 23 shows chordae 240 extending from apertures like those shown at 48 in FIG. 21.



FIG. 24 illustrates the point that variations in stent cell 46 geometry around the circumference of annular structure 40 can reduce impingement on or of the aortic valve, chordae, and the coronary sinus. Additionally, extended portions (e.g., 244) of some cells may allow for greater holding force in certain parts of the anatomy such as in the atrial appendage.



FIGS. 25 and 26 show other variations in the shape of annular structure 40 that can allow for better conformance to the mitral valve anatomy. For example, FIG. 25 shows an asymmetric shape, while FIG. 26 shows a symmetric saddle shape.



FIG. 27 shows that a valve 210 with an elliptical shape may also conform better to the mitral valve anatomy than a circular-shaped valve. Additionally, instead of a tri-leaflet design, FIG. 27 shows that a bi-leaflet design 100′ can be used (leaflets shown open in FIG. 27). Once again, chordae 220 can be attached at commissure posts 50, and the edge of cuff 110 can be contoured to follow the edge of stent 40.


Although the structures shown in FIGS. 18-27 are described primarily as mitral valve structures, it will be understood that this is only illustrative, and that various structures and principles illustrated by or in these FIGS. can be employed in other types of prosthetic heart valves (e.g., in prosthetic aortic valves).


Briefly recapitulating some of what has been said in somewhat different terms, it will be seen that in many embodiments of the invention, at least the portion 40 of the prosthetic valve that goes in the patient's native valve annulus includes an annular array of generally diamond-shaped cells 46. Upstream apex portions 144 of at least some of these cells are resiliently biased to deflect radially outwardly from at least some other portions of structure 40. Downstream apex portions 142 of at least some of these cells are similarly resiliently biased to deflect radially outwardly from at least some other portions of structure 40. This allows the valve to clamp tissue of the patient between the upstream and downstream apex portions that thus deflect outwardly.


Each of the above-mentioned apex portions comprises two spaced-apart members that join at an apex of that apex portion. For example, in FIG. 7 the two spaced-apart members of one representative downstream apex portion are identified by reference letters b and c, and the apex where those members join is identified by reference letter a.


Still more particularly, the resiliently biased, radially outward deflection of each upstream apex portion 144 typically includes a downstream component of motion of that upstream apex portion (in addition to a radially outward component of motion). This is illustrated, for example, by the arcuate arrows 44 in FIGS. 1-3. Similarly, the resiliently biased, radially outward deflection of each of downstream apex portion 142 typically includes an upstream component of motion of that downstream apex portion (in addition to a radially outward component of motion). This is illustrated, for example, by the arcuate arrows 42 in FIGS. 1-3. The result of this is that the upstream and downstream apex portions begin as jaws that are relatively far apart and wide open. They then effectively pivot toward one another to clamp tissue therebetween.


References herein to an annular perimeter of a structure being changeable in length mean that the perimeter increases or decreases in size without going through any major topological change. In other words, the shape of the structure remains basically the same, and only the perimeter size changes. For example, the shape may be always basically circular. There is no folding or wrapping of the structure to change its perimeter size. The shape either basically shrinks down or expands out. A minor exception to the foregoing is that ellipses and circles are regarded herein as having the same basic topology. Thus an ellipse may shrink to a circle, for example, without that constituting “a major topological change.”


It will be understood that the foregoing is only illustrative of the principles of the invention, and that various modifications can be made by those skilled in the art without departing from the scope and spirit of the invention. For example, the particular patterns of stent cells like 22 and 46 shown herein are only illustrative, and many other stent configurations can be used instead if desired. It will be appreciated that the valves of this invention can, if desired, be implanted in a patient less invasively. For example, the valves of this invention can be implanted percutaneously, trans-apically, or surgically, and with or without resected and/or debrided leaflets. Depending on the embodiment, the valve can be collapsed in a variety of configurations before deployment in a single- or multi-stage process. Access can be achieved, for example, through the femoral artery, abdominal aorta, or the apex of the heart.

Claims
  • 1. A prosthetic heart valve, comprising: a stent having an inflow end, an outflow end, an expanded condition and a collapsed condition, the stent including an annularly continuous annulus portion adjacent the inflow end and a plurality of commissure posts each having a connected end connected to the annulus portion and a free end, the annulus portion including a plurality of closed perimeter diamond-shaped cells, each cell having an upstream apex portion directly connected to a downstream apex portion at connection points, the upstream apex portion having an upstream apex and the downstream apex portion having a downstream apex, the stent being devoid of structure between adjacent ones of the commissure posts from the connected ends to the free ends, the upstream apex portion of each cell in a group of the cells being resiliently biased to deflect radially outwardly from the connection points and the downstream apex portion of each cell in the group of the cells being resiliently biased to deflect radially outwardly from the connection points;an expandable and collapsible valve element mounted within the stent; anda skirt connected to the annulus portion of the stent.
  • 2. The prosthetic heart valve as claimed in claim 1, wherein the skirt extends annularly around the annulus portion and has a first annular edge positioned downstream from the upstream apices and a second annular edge positioned upstream from the downstream apices.
  • 3. The prosthetic heart valve as claimed in claim 2, wherein each upstream apex in a group of the upstream apices includes a barb and each downstream apex in a group of the downstream apices includes a barb.
  • 4. The prosthetic heart valve as claimed in claim 2, further comprising a barb on each of the upstream apices and on each of the downstream apices.
  • 5. The prosthetic heart valve as claimed in claim 1, wherein the skirt includes a chamber disposed in a circumferential direction around the annulus portion of the stent.
  • 6. The prosthetic heart valve as claimed in claim 5, wherein the chamber is filled with a polymeric substance.
  • 7. The prosthetic heart valve as claimed in claim 1, wherein the skirt has an inflow end, an outflow end, and a length in a longitudinal direction of the stent that is less than a length of the annulus portion so that the skirt outflow end is positioned upstream from the downstream apices of the annulus portion.
  • 8. The prosthetic heart valve as claimed in claim 1, wherein the skirt covers the annulus portion of the stent from the upstream apices to the downstream apices.
  • 9. The prosthetic heart valve as claimed in claim 1, wherein the skirt includes an inner wall disposed in a circumferential direction around the annulus portion of the stent, and a closed toroidal section disposed in the circumferential direction around the inner wall.
  • 10. The prosthetic heart valve as claimed in claim 9, wherein the inner wall of the skirt has a first length in the longitudinal direction of the stent and the toroidal section has a second length in the longitudinal direction of the stent, the second length being less than the first length.
  • 11. The prosthetic heart valve as claimed in claim 1, wherein each of the commissure posts includes an aperture at the free end.
  • 12. A prosthetic heart valve, comprising: a stent having an inflow end, an outflow end, an expanded condition and a collapsed condition, the stent including an annularly continuous annulus portion adjacent the inflow end, an annularly continuous aortic portion adjacent the outflow end, and a plurality of commissure posts each having a first end connected to the annulus portion and a second end connected to the aortic portion, the annulus portion including a plurality of closed perimeter diamond-shaped cells, each cell having an upstream apex portion directly connected to a downstream apex portion at connection points, the upstream apex portion having an upstream apex and the downstream apex portion having a downstream apex, the stent being devoid of structure between adjacent ones of the commissure posts from the first ends to the second ends, the upstream apex portion of each cell in a group of the cells being resiliently biased to deflect radially outwardly from the connection points and the downstream apex portion of each cell in the group of the cells being resiliently biased to defect radially outwardly from the connection points;an expandable and collapsible valve element mounted within the stent; anda skirt connected to the annulus portion of the stent.
  • 13. The prosthetic heart valve as claimed in claim 12, wherein the skirt extends annularly around the annulus portion and has a first annular edge positioned downstream from the upstream apices and a second annular edge positioned upstream from the downstream apices.
  • 14. The prosthetic heart valve as claimed in claim 13, further comprising a barb on each of the upstream apices and on each of the downstream apices.
  • 15. The prosthetic heart valve as claimed in claim 12, wherein the skirt includes an inner wall disposed in a circumferential direction around the annulus portion of the stent, and a closed toroidal section disposed in the circumferential direction around the inner wall.
  • 16. The prosthetic heart valve as claimed in claim 15, wherein the inner wall of the skirt has a first length in the longitudinal direction of the stent and the toroidal section has a second length in the longitudinal direction of the stent, the second length being less than the first length.
  • 17. The prosthetic heart valve as claimed in claim 15, wherein the inner wall has a first annular edge positioned downstream from the upstream apices and a second annular edge positioned upstream from the downstream apices.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/688,357, filed Apr. 16, 2015, which is a continuation of U.S. patent application Ser. No. 11/906,133, filed Sep. 28, 2007, now U.S. Pat. No. 9,532,868, the disclosures of which are hereby incorporated herein by reference.

US Referenced Citations (603)
Number Name Date Kind
3409013 Berry Nov 1968 A
3467102 Fogarty et al. Sep 1969 A
3548417 Kischer Dec 1970 A
3587115 Shiley Jun 1971 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3755823 Hancock Sep 1973 A
3983581 Angell et al. Oct 1976 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4106129 Carpentier et al. Aug 1978 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4275469 Gabbay Jun 1981 A
4297749 Davis et al. Nov 1981 A
RE30912 Hancock Apr 1982 E
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4373216 Klawitter Feb 1983 A
4406022 Roy Sep 1983 A
4470157 Love Sep 1984 A
4491986 Gabbay Jan 1985 A
4535483 Klawitter et al. Aug 1985 A
4574803 Storz Mar 1986 A
4592340 Boyles Jun 1986 A
4605407 Black et al. Aug 1986 A
4612011 Kautzky Sep 1986 A
4643732 Pietsch et al. Feb 1987 A
4655771 Wallsten Apr 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4733665 Palmaz Mar 1988 A
4759758 Gabbay Jul 1988 A
4762128 Rosenbluth Aug 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4796629 Grayzel Jan 1989 A
4797901 Goerne et al. Jan 1989 A
4829990 Thuroff et al. May 1989 A
4851001 Taheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4922905 Strecker May 1990 A
4966604 Reiss Oct 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne et al. Oct 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5192297 Hull Mar 1993 A
5258023 Reger Nov 1993 A
5266073 Wall Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5295958 Shturman Mar 1994 A
5332402 Teitelbaum Jul 1994 A
5360444 Kusuhara Nov 1994 A
5370685 Stevens Dec 1994 A
5397351 Pavcnik et al. Mar 1995 A
5411055 Kane May 1995 A
5411552 Andersen et al. May 1995 A
5415664 Pinchuk May 1995 A
5415667 Frater May 1995 A
5443446 Shturman Aug 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5480424 Cox Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5545209 Roberts et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554185 Block et al. Sep 1996 A
5571175 Vanney et al. Nov 1996 A
5591185 Kilmer et al. Jan 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5628786 Banas et al. May 1997 A
5639274 Fischell et al. Jun 1997 A
5665115 Cragg Sep 1997 A
5693088 Lazarus Dec 1997 A
5716417 Girard et al. Feb 1998 A
5728068 Leone et al. Mar 1998 A
5749890 Shaknovich May 1998 A
5756476 Epstein et al. May 1998 A
5769812 Stevens et al. Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5776188 Shepherd et al. Jul 1998 A
5800508 Goicoechea et al. Sep 1998 A
5840081 Andersen et al. Nov 1998 A
5843161 Solovay Dec 1998 A
5843167 Dwyer et al. Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5925063 Khosravi Jul 1999 A
5928281 Huynh et al. Jul 1999 A
5935163 Gabbay Aug 1999 A
5957949 Leonhardt et al. Sep 1999 A
5961549 Nguyen et al. Oct 1999 A
6015431 Thornton et al. Jan 2000 A
6027525 Suh et al. Feb 2000 A
6045576 Starr et al. Apr 2000 A
6077297 Robinson et al. Jun 2000 A
6083257 Taylor et al. Jul 2000 A
6090140 Gabbay Jul 2000 A
6110198 Fogarty et al. Aug 2000 A
6132473 Williams et al. Oct 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6174327 Mertens et al. Jan 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6214036 Letendre et al. Apr 2001 B1
6217585 Houser et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6231602 Carpentier et al. May 2001 B1
6245102 Jayaraman Jun 2001 B1
6264691 Gabbay Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6306164 Kujawski Oct 2001 B1
6312465 Griffin et al. Nov 2001 B1
6350277 Kocur Feb 2002 B1
6352554 De Paulis Mar 2002 B2
6368348 Gabbay Apr 2002 B1
6419695 Gabbay Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6482228 Norred Nov 2002 B1
6488702 Besselink Dec 2002 B1
6488704 Connelly et al. Dec 2002 B1
6517576 Gabbay Feb 2003 B2
6533810 Hankh et al. Mar 2003 B2
6569196 Vesely May 2003 B1
6582462 Andersen et al. Jun 2003 B1
6582464 Gabbay Jun 2003 B2
6605112 Moll et al. Aug 2003 B1
6610088 Gabbay Aug 2003 B1
6623518 Thompson et al. Sep 2003 B2
6652578 Bailey et al. Nov 2003 B2
6685625 Gabbay Feb 2004 B2
6712836 Berg et al. Mar 2004 B1
6716244 Klaco Apr 2004 B2
6719789 Cox Apr 2004 B2
6726715 Sutherland Apr 2004 B2
6729356 Baker et al. May 2004 B1
6730118 Spenser May 2004 B2
6733525 Yang et al. May 2004 B2
6767362 Schreck Jul 2004 B2
6780510 Ogle et al. Aug 2004 B2
6783556 Gabbay Aug 2004 B1
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6814754 Greenhalgh Nov 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof et al. Dec 2004 B1
6837902 Nguyen et al. Jan 2005 B2
6860901 Baker et al. Mar 2005 B1
6869444 Gabbay Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6893460 Spenser et al. May 2005 B2
6908481 Cribier Jun 2005 B2
6911040 Johnson et al. Jun 2005 B2
6951573 Dilling Oct 2005 B1
7018406 Seguin et al. Mar 2006 B2
7018408 Bailey et al. Mar 2006 B2
7025780 Gabbay Apr 2006 B2
7041132 Quijano et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7101396 Artof et al. Sep 2006 B2
7137184 Schreck Nov 2006 B2
7147663 Berg et al. Dec 2006 B1
7160322 Gabbay Jan 2007 B2
7195641 Palmaz et al. Mar 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7247167 Gabbay Jul 2007 B2
7252682 Seguin Aug 2007 B2
7261732 Justino Aug 2007 B2
7264632 Wright et al. Sep 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7276078 Spenser et al. Oct 2007 B2
7276084 Yang et al. Oct 2007 B2
7311730 Gabbay Dec 2007 B2
7320704 Lashinski et al. Jan 2008 B2
7329278 Seguin et al. Feb 2008 B2
7331991 Kheradvar et al. Feb 2008 B2
7338520 Bailey et al. Mar 2008 B2
7374571 Pease et al. May 2008 B2
7374573 Gabbay May 2008 B2
7381218 Schreck Jun 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7393360 Spenser et al. Jul 2008 B2
7399315 Iobbi Jul 2008 B2
7452371 Pavcnik et al. Nov 2008 B2
7462191 Spenser et al. Dec 2008 B2
7481838 Carpentier et al. Jan 2009 B2
7510572 Gabbay Mar 2009 B2
7510575 Spenser et al. Mar 2009 B2
7524331 Birdsall Apr 2009 B2
7527647 Spence May 2009 B2
7530995 Quijano et al. May 2009 B2
7534261 Friedman May 2009 B2
RE40816 Taylor et al. Jun 2009 E
7585321 Cribier Sep 2009 B2
7597711 Drews et al. Oct 2009 B2
7628805 Spenser et al. Dec 2009 B2
7682390 Seguin Mar 2010 B2
7708775 Rowe et al. May 2010 B2
7717955 Lane et al. May 2010 B2
7731742 Schlick et al. Jun 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7780725 Haug et al. Aug 2010 B2
7799069 Bailey et al. Sep 2010 B2
7803185 Gabbay Sep 2010 B2
7824442 Salahieh et al. Nov 2010 B2
7837727 Goetz et al. Nov 2010 B2
7846203 Cribier Dec 2010 B2
7846204 Letac et al. Dec 2010 B2
7857845 Stacchino et al. Dec 2010 B2
7871435 Carpentier et al. Jan 2011 B2
7892281 Seguin et al. Feb 2011 B2
7914569 Nguyen et al. Mar 2011 B2
7951197 Lane et al. May 2011 B2
7959666 Salahieh et al. Jun 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7959674 Shu et al. Jun 2011 B2
7967857 Lane Jun 2011 B2
7972378 Tabor et al. Jul 2011 B2
7988724 Salahieh et al. Aug 2011 B2
7993394 Hariton et al. Aug 2011 B2
8016877 Seguin et al. Sep 2011 B2
D648854 Braido Nov 2011 S
8048153 Salahieh et al. Nov 2011 B2
8052741 Bruszewski et al. Nov 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8052750 Tuval et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8075611 Millwee et al. Dec 2011 B2
8083793 Lane et al. Dec 2011 B2
D652926 Braido Jan 2012 S
D652927 Braido et al. Jan 2012 S
D653341 Braido et al. Jan 2012 S
D653342 Braido et al. Jan 2012 S
D653343 Ness et al. Jan 2012 S
D654169 Braido Feb 2012 S
D654170 Braido et al. Feb 2012 S
8137398 Tuval et al. Mar 2012 B2
8142497 Friedman Mar 2012 B2
D660432 Braido May 2012 S
D660433 Braido et al. May 2012 S
D660967 Braido et al. May 2012 S
8182528 Salahieh et al. May 2012 B2
8221493 Boyle et al. Jul 2012 B2
8226710 Nguyen et al. Jul 2012 B2
8230717 Matonick Jul 2012 B2
8231670 Salahieh et al. Jul 2012 B2
8252051 Chau et al. Aug 2012 B2
8308798 Pintor et al. Nov 2012 B2
8313525 Tuval et al. Nov 2012 B2
8323335 Rowe et al. Dec 2012 B2
8323336 Hill et al. Dec 2012 B2
8343213 Salahieh et al. Jan 2013 B2
8348995 Tuval et al. Jan 2013 B2
8348996 Tuval et al. Jan 2013 B2
8348998 Pintor et al. Jan 2013 B2
8349000 Schreck Jan 2013 B2
8366769 Huynh et al. Feb 2013 B2
8403983 Quadri et al. Mar 2013 B2
8408214 Spenser Apr 2013 B2
8414643 Tuval et al. Apr 2013 B2
8425593 Braido Apr 2013 B2
8449599 Chau et al. May 2013 B2
8449604 Moaddeb et al. May 2013 B2
8454685 Hariton et al. Jun 2013 B2
8454686 Alkhatib Jun 2013 B2
8465540 Straubinger et al. Jun 2013 B2
8500798 Rowe et al. Aug 2013 B2
8512396 Styrc Aug 2013 B2
8568474 Yeung et al. Oct 2013 B2
8568477 Lashinski et al. Oct 2013 B2
8579962 Salahieh et al. Nov 2013 B2
8579966 Seguin et al. Nov 2013 B2
8585755 Chau et al. Nov 2013 B2
8591575 Cribier Nov 2013 B2
8597349 Alkhatib Dec 2013 B2
8603159 Seguin et al. Dec 2013 B2
8603160 Salahieh et al. Dec 2013 B2
8613765 Bonhoeffer et al. Dec 2013 B2
8623074 Ryan Jan 2014 B2
8652204 Quill et al. Feb 2014 B2
8663322 Keranen Mar 2014 B2
8668733 Haug et al. Mar 2014 B2
8673000 Tabor et al. Mar 2014 B2
8685080 White Apr 2014 B2
8685086 Navia et al. Apr 2014 B2
8728154 Alkhatib May 2014 B2
8747459 Nguyen et al. Jun 2014 B2
8747460 Tuval et al. Jun 2014 B2
8747461 Centola Jun 2014 B2
8764820 Dehdashtian et al. Jul 2014 B2
8771345 Tuval et al. Jul 2014 B2
8784481 Alkhatib et al. Jul 2014 B2
8795357 Yohanan et al. Aug 2014 B2
8801776 House et al. Aug 2014 B2
8808356 Braido et al. Aug 2014 B2
8828078 Salahieh et al. Sep 2014 B2
8834563 Righini Sep 2014 B2
8840661 Manasse Sep 2014 B2
8840663 Salahieh et al. Sep 2014 B2
8845721 Braido et al. Sep 2014 B2
8876894 Tuval et al. Nov 2014 B2
8876895 Tuval et al. Nov 2014 B2
8920492 Stacchino et al. Dec 2014 B2
8940040 Shahriari Jan 2015 B2
8945209 Bonyuet et al. Feb 2015 B2
8961595 Alkhatib Feb 2015 B2
8974523 Thill et al. Mar 2015 B2
8974524 Yeung et al. Mar 2015 B2
8986375 Garde et al. Mar 2015 B2
8992608 Haug et al. Mar 2015 B2
9095432 Cribier Aug 2015 B2
9132007 Menk et al. Sep 2015 B2
9168129 Valdez et al. Oct 2015 B2
9186249 Rolando et al. Nov 2015 B2
9308087 Lane et al. Apr 2016 B2
9393110 Levi et al. Jul 2016 B2
9414910 Lim Aug 2016 B2
9636222 Oslund May 2017 B2
9668858 Morin et al. Jun 2017 B2
9675451 Garde et al. Jun 2017 B2
9681949 Braido et al. Jun 2017 B2
9713529 Lane Jul 2017 B2
9839513 Essinger et al. Dec 2017 B2
9889004 Braido Feb 2018 B2
10413401 Eberhardt et al. Sep 2019 B2
11109964 Hacohen Sep 2021 B2
11337800 Schreck May 2022 B2
11504231 Carlino Nov 2022 B2
20010007956 Letac et al. Jul 2001 A1
20010010017 Letac et al. Jul 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010027338 Greenberg Oct 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20020032481 Gabbay Mar 2002 A1
20020036220 Gabbay Mar 2002 A1
20020055774 Liddicoat May 2002 A1
20020138138 Yang Sep 2002 A1
20020173842 Buchanan Nov 2002 A1
20030023303 Palmaz et al. Jan 2003 A1
20030027332 Lafrance et al. Feb 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030040792 Gabbay Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030100939 Yodfat et al. May 2003 A1
20030109924 Cribier Jun 2003 A1
20030114913 Spenser et al. Jun 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20030167089 Lane Sep 2003 A1
20030199963 Tower et al. Oct 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030236567 Elliot Dec 2003 A1
20030236568 Hojeibane et al. Dec 2003 A1
20040033364 Spiridigliozzi et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040082989 Cook et al. Apr 2004 A1
20040093060 Seguin May 2004 A1
20040093075 Kuehne May 2004 A1
20040111111 Lin Jun 2004 A1
20040186565 Schreck Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040260389 Case et al. Dec 2004 A1
20050033398 Seguin Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050075718 Nguyen et al. Apr 2005 A1
20050075725 Rowe Apr 2005 A1
20050096726 Sequin et al. May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050137682 Justino Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137699 Salahieh et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050177228 Solem et al. Aug 2005 A1
20050192665 Spenser et al. Sep 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203605 Dolan Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050251251 Cribier Nov 2005 A1
20050256566 Gabbay Nov 2005 A1
20050283231 Haug et al. Dec 2005 A1
20060004439 Spenser et al. Jan 2006 A1
20060004442 Spenser et al. Jan 2006 A1
20060008497 Gabbay Jan 2006 A1
20060025855 Lashinski et al. Feb 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060074484 Huber Apr 2006 A1
20060122692 Gilad et al. Jun 2006 A1
20060129235 Seguin et al. Jun 2006 A1
20060149350 Patel et al. Jul 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060173532 Flagle et al. Aug 2006 A1
20060178731 Tower Aug 2006 A1
20060178740 Stacchino Aug 2006 A1
20060195180 Kheradvar et al. Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060195186 Drews et al. Aug 2006 A1
20060206202 Bonhoeffer et al. Sep 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060241744 Beith Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060259120 Vongphakdy et al. Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060259135 Navia et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060276813 Greenberg Dec 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20070010876 Salahieh et al. Jan 2007 A1
20070027534 Bergheim et al. Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070050021 Johnson Mar 2007 A1
20070055358 Krolik et al. Mar 2007 A1
20070067029 Gabbay Mar 2007 A1
20070073387 Forster et al. Mar 2007 A1
20070093890 Eliasen et al. Apr 2007 A1
20070100435 Case et al. May 2007 A1
20070112355 Salahieh et al. May 2007 A1
20070112422 Dehdashtian May 2007 A1
20070118210 Pinchuk May 2007 A1
20070118214 Salahieh et al. May 2007 A1
20070142907 Moaddeb et al. Jun 2007 A1
20070162100 Gabbay Jul 2007 A1
20070162107 Haug et al. Jul 2007 A1
20070168022 Eldridge Jul 2007 A1
20070198097 Zegdi Aug 2007 A1
20070203503 Salahieh et al. Aug 2007 A1
20070208550 Cao et al. Sep 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070239265 Birdsall Oct 2007 A1
20070239271 Nguyen Oct 2007 A1
20070244545 Birdsall et al. Oct 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070255398 Yang et al. Nov 2007 A1
20070270944 Bergheim et al. Nov 2007 A1
20070282436 Pinchuk Dec 2007 A1
20070288087 Fearnot et al. Dec 2007 A1
20080021546 Patz et al. Jan 2008 A1
20080021552 Gabbay Jan 2008 A1
20080039934 Styrc Feb 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071363 Tuval Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080077236 Letac et al. Mar 2008 A1
20080082164 Friedman Apr 2008 A1
20080097595 Gabbay Apr 2008 A1
20080114452 Gabbay May 2008 A1
20080125853 Bailey et al. May 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080147179 Cai et al. Jun 2008 A1
20080147183 Styrc Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080208327 Rowe Aug 2008 A1
20080208329 Bishop et al. Aug 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080243246 Ryan et al. Oct 2008 A1
20080255662 Stacchino et al. Oct 2008 A1
20080262602 Wilk et al. Oct 2008 A1
20080269879 Sathe et al. Oct 2008 A1
20090099653 Suri et al. Apr 2009 A1
20090112309 Jaramillo et al. Apr 2009 A1
20090138079 Tuval et al. May 2009 A1
20090171447 Von Segesser et al. Jul 2009 A1
20090192599 Lane et al. Jul 2009 A1
20090234443 Ottma et al. Sep 2009 A1
20090248149 Gabbay Oct 2009 A1
20090264997 Salahieh et al. Oct 2009 A1
20090276027 Glynn Nov 2009 A1
20090287296 Manasse Nov 2009 A1
20090287299 Tabor et al. Nov 2009 A1
20100004740 Seguin et al. Jan 2010 A1
20100036484 Hariton et al. Feb 2010 A1
20100049306 House et al. Feb 2010 A1
20100082094 Quadri et al. Apr 2010 A1
20100087907 Lattouf Apr 2010 A1
20100100176 Elizondo et al. Apr 2010 A1
20100114305 Kang et al. May 2010 A1
20100131055 Case et al. May 2010 A1
20100168778 Braido Jul 2010 A1
20100168839 Braido et al. Jul 2010 A1
20100168844 Toomes et al. Jul 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100204781 Alkhatib Aug 2010 A1
20100204785 Alkhatib Aug 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100234940 Dolan Sep 2010 A1
20100249911 Alkhatib Sep 2010 A1
20100249923 Alkhatib et al. Sep 2010 A1
20100262231 Tuval et al. Oct 2010 A1
20100286768 Alkhatib Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20110022157 Essinger et al. Jan 2011 A1
20110029072 Gabbay Feb 2011 A1
20110054466 Rothstein et al. Mar 2011 A1
20110098800 Braido et al. Apr 2011 A1
20110098802 Braido et al. Apr 2011 A1
20110137397 Chau et al. Jun 2011 A1
20110166636 Rowe Jul 2011 A1
20110172765 Nguyen et al. Jul 2011 A1
20110208283 Rust Aug 2011 A1
20110264206 Tabor Oct 2011 A1
20110282439 Thill et al. Nov 2011 A1
20110301692 Seguin Dec 2011 A1
20110319988 Schankereli et al. Dec 2011 A1
20120035719 Forster et al. Feb 2012 A1
20120035722 Tuval Feb 2012 A1
20120046742 Tuval et al. Feb 2012 A1
20120078347 Braido et al. Mar 2012 A1
20120078353 Quadri Mar 2012 A1
20120078357 Conklin Mar 2012 A1
20120083878 Sequin et al. Apr 2012 A1
20120083879 Eberhardt et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120123529 Levi et al. May 2012 A1
20120179244 Schankereli et al. Jul 2012 A1
20120215303 Quadri et al. Aug 2012 A1
20120232646 Agathos Sep 2012 A1
20120271398 Essinger et al. Oct 2012 A1
20120277856 Spenser et al. Nov 2012 A1
20120296418 Bonyuet et al. Nov 2012 A1
20120303116 Gorman, III et al. Nov 2012 A1
20120316642 Yu et al. Dec 2012 A1
20130018458 Yohanan et al. Jan 2013 A1
20130023984 Conklin Jan 2013 A1
20130144375 Giasolli Jun 2013 A1
20130150956 Yohanan et al. Jun 2013 A1
20130197622 Mitra et al. Aug 2013 A1
20130204359 Thubrikar et al. Aug 2013 A1
20130211508 Lane et al. Aug 2013 A1
20130218267 Braido et al. Aug 2013 A1
20130274870 Lombardi et al. Oct 2013 A1
20130274873 Delaloye et al. Oct 2013 A1
20130331929 Mitra et al. Dec 2013 A1
20130338765 Braido et al. Dec 2013 A1
20130345786 Behan Dec 2013 A1
20140121763 Duffy et al. May 2014 A1
20140142694 Tabor et al. May 2014 A1
20140155997 Braido Jun 2014 A1
20140194981 Menk et al. Jul 2014 A1
20140214157 Bortlein et al. Jul 2014 A1
20140214159 Vidlund et al. Jul 2014 A1
20140228946 Chau et al. Aug 2014 A1
20140277428 Skemp et al. Sep 2014 A1
20140303719 Cox et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140343671 Yohanan et al. Nov 2014 A1
20140350663 Braido et al. Nov 2014 A1
20140350665 Braido et al. Nov 2014 A1
20140350667 Braido et al. Nov 2014 A1
20140350668 Delaloye et al. Nov 2014 A1
20140350669 Gillespie et al. Nov 2014 A1
20150216658 Braido Aug 2015 A1
20150305860 Wang et al. Oct 2015 A1
20150320556 Levi et al. Nov 2015 A1
20160354201 Keogh Dec 2016 A1
Foreign Referenced Citations (115)
Number Date Country
2246526 Mar 1973 DE
19532846 Mar 1997 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049814 Apr 2002 DE
10049815 Apr 2002 DE
10121210 Nov 2002 DE
102005003632 Aug 2006 DE
202008009610 Dec 2008 DE
0103546 Mar 1984 EP
0144167 Jun 1985 EP
0592410 Apr 1994 EP
0850607 Jul 1998 EP
0597967 Dec 1999 EP
1000590 May 2000 EP
1057460 Dec 2000 EP
1088529 Apr 2001 EP
1360942 Nov 2003 EP
1570809 Sep 2005 EP
1584306 Oct 2005 EP
1598031 Nov 2005 EP
1926455 Jun 2008 EP
2047824 Apr 2009 EP
2059192 May 2009 EP
2254513 Dec 2010 EP
2537487 Dec 2012 EP
2620125 Jul 2013 EP
2749254 Jul 2014 EP
2815725 Dec 2014 EP
2788217 Jul 2000 FR
2850008 Jul 2004 FR
2847800 Oct 2005 FR
2056023 Mar 1981 GB
2008541865 Nov 2008 JP
2011500241 Jan 2011 JP
2011522634 Aug 2011 JP
2011528256 Nov 2011 JP
2012504031 Feb 2012 JP
158988 Nov 1963 SU
1271508 Nov 1986 SU
1371700 Feb 1988 SU
1457921 Feb 1989 SU
9117720 Nov 1991 WO
9217118 Oct 1992 WO
9301768 Feb 1993 WO
9716133 May 1997 WO
9724080 Jul 1997 WO
9832412 Jul 1998 WO
199829057 Jul 1998 WO
9913801 Mar 1999 WO
9933414 Jul 1999 WO
9940964 Aug 1999 WO
9947075 Sep 1999 WO
2000018333 Apr 2000 WO
200041652 Jul 2000 WO
200047139 Aug 2000 WO
0128459 Apr 2001 WO
2001035878 May 2001 WO
200149213 Jul 2001 WO
0154625 Aug 2001 WO
0156500 Aug 2001 WO
200162189 Aug 2001 WO
2001054624 Aug 2001 WO
0164137 Sep 2001 WO
0166035 Sep 2001 WO
0166037 Sep 2001 WO
0176510 Oct 2001 WO
2002022054 Mar 2002 WO
0236048 May 2002 WO
2002041789 May 2002 WO
0247575 Jun 2002 WO
2002043620 Jun 2002 WO
2002049540 Jun 2002 WO
02067782 Sep 2002 WO
03037222 May 2003 WO
03047468 Jun 2003 WO
2003075799 Sep 2003 WO
2004016200 Feb 2004 WO
2005062980 Jul 2005 WO
2005070343 Aug 2005 WO
2005087140 Sep 2005 WO
2006014233 Feb 2006 WO
2006034008 Mar 2006 WO
2006041505 Apr 2006 WO
06073626 Jul 2006 WO
2006124649 Nov 2006 WO
2006127765 Nov 2006 WO
2006128193 Nov 2006 WO
2007053243 May 2007 WO
07071436 Jun 2007 WO
2007081820 Jul 2007 WO
2008005405 Jan 2008 WO
2008035337 Mar 2008 WO
08070797 Jun 2008 WO
2008100600 Aug 2008 WO
2008147964 Dec 2008 WO
2008150529 Dec 2008 WO
2009024859 Feb 2009 WO
2009042196 Apr 2009 WO
2009045338 Apr 2009 WO
2009053497 Apr 2009 WO
2009061389 May 2009 WO
2009149462 Dec 2009 WO
2010008548 Jan 2010 WO
2010008549 Jan 2010 WO
2010037141 Apr 2010 WO
2010096176 Aug 2010 WO
2010098857 Sep 2010 WO
2010141847 Dec 2010 WO
2011057087 May 2011 WO
2012032187 Mar 2012 WO
2012161786 Nov 2012 WO
Non-Patent Literature Citations (67)
Entry
Sigwart, U., “An Overview of Intravascular Stents: Old and New,” Chapter 48, Interventional Cardiology, 2nd Edition, W.B. Saunders Company, Philadelphia, PA, © 1994, 1990, pp. 803-815.
Swiatkiewicz, et al., “Percutaneous closure of mitral perivalvular leak,” Kardiologia Polska, vol. 67, No. 7, pp. 762-764, Jul. 2009.
U.S. Appl. No. 13/572,842, filed Aug. 13, 2012, Kovalsky.
Uchida, Barry T., et al., “Modifications of Gianturco Expandable Wire Stents,” AJR:150, May 1988, Dec. 3, 1987, pp. 1185-1187.
Urban, M.D., Philip, “Coronary Artery Stenting,” Editions Medecine et Hygiene, Geneve, 1991, pp. 5-47.
Watt, A.H., et al. “Intravenous Adenosine in the Treatment of Supraventricular Tachycardia; a Dose-Ranging Study and Interaction with Dipyridamole,” British Journal of Clinical Pharmacology (1986), 21, 227-230.
Wheatley, M.D., David J., “Valve Prostheses,” Rob & Smith's Operative Surgery, Fourth Edition, pp. 415-424, Butterworths 1986.
Zegdi, R., MD, PhD et al., “Is It Reasonable to Treat All Calcified Stenotic Aortic Valves With a Valved Stent?” J. of the American College of Cardiology, Feb. 5, 2008, pp. 579-584, vol. 51, No. 5.
78. Heart repairs without surgery. Minimally invasive procedures aim to correct valve leakage. PubMed ID 15586429, Heart Advisor, Sep. 2004.
Al Zaibag, Muayed, et al., “Percutaneous Balloon Valvotomy in Tricuspid Stenosis,” British Heart Journal, Jan. 1987, vol. 57, No. 1, pp. 51-53.
Al-Khaja, N., et al., “Eleven Years' Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications,” European Journal of Cardiothoracic Surgery 3:305-311, Jun. 30, 2009.
Almagor, Y. et al., “Balloon Expandable Stent Implantation in Stenotic Right Heart Valved Conduits,” Journal of the American College of Cardiology, Nov. 1, 1990, 16(6):1310-1314.
Andersen, H. R., “History of Percutaneous Aortic Valve Prosthesis,” Herz, Aug. 2009, 34(5):343-346.
Andersen, H.R. et al, “Transluminal implantation of artificial heart valves,” European Heart Journal, May 1992, pp. 704-708, vol. 13, No. 5.
Andersen, H.R., “Transluminal Catheter Implanted Prosthetic Heart Valves,” International Journal of Angiology, Mar. 1998, pp. 102-106, vol. 7, No. 2.
Benchimol, Alberto, et al., “Simultaneous Left Ventricular Echocardiography and Aortic Blood Velocity During Rapid Right Ventricular Pacing in Man,” The American Journal of the Medical Sciences, Jan.-Feb. 1977 vol. 273, No. 1, pp. 55-62.
Braido et al., U.S. Appl. No. 29/375,243, filed Sep. 20, 2010, titled “Surgical Stent Assembly”.
Braido, Peter Nicholas, U.S. Appl. No. 29/375,260, filed Sep. 20, 2010, titled “Forked Ends”.
Buellesfeld, et al., “Treatment of paravalvular leaks through inverventional techniques,” Multimed Man Cardiothorac Surg., Department of Cardiology, Ben University Hospital, pp. 1-8, Jan. 2011.
Bullesfeld et al., Percutaneous Implantation of the First Repositionable Aortic Valve Prosthesis in a Patient With Severe Aortic Stenosis, Catheterization & Cardiovascular Interventions 71:579-84 (2008).
Catheter-implanted prosthetic heart valves, Knudsen, L.L., et al., The International Journal of Artificial Organs, vol. 16, No. 5 1993, pp. 253-262.
Curriculum Vitae of Robert A. Ersek, M.D., FACS, Jul. 10, 2009, http://www.ersek.com/rae-cv.htm.
De Cicco, et al., “Aortic valve periprosthetic leakage: anatomic observations and surgical results,” The Annals of thoracic surgery, vol. 79, No. 5, pp. 1480-1485, May 2005.
Dotter, C. T. et al., “Transluminal Treatment of Arteriosclerotic Obstruction. Description of a New Technic and a Preliminary Report of its Application,” Circulation, Nov. 1964, 30:654-670.
European Communication for Application No. 09788918.2 dated Jun. 29, 2015.
Evidence—Anlage 3 (Photograph).
Extended European Search Report for Application No. 14180622.4 dated Nov. 21, 2014.
Extended European Search Report for Application No. 14180623.2 dated Nov. 24, 2014.
Extended European Search Report for Application No. 14180625.7 dated Nov. 24, 2014.
Grube et al., “Percutaneous Implantation of the CoreValve Self-Expanding Valve Prosthesis in High-Risk Patients With Aortic Valve Disease” (2006).
Gössl,et al., “Percutaneous treatment of aortic and mitral valve paravalvular regurgitation,” Current Cardiology Reports, vol. 15, No. 8., pp. 1-8, Aug. 2013.
Heart Advisor, “Heart repairs without surgery. Minimally invasive procedures aim to correct valve leakage,” Sep. 2004, pp. 4-5, PubMed ID 15586429.
Hourihan, et al., “Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks,” Journal of the American College of Cardiology, vol. 20, No. 6, pp. 1371-1377, Nov. 1992.
Inoune, M.D., Kanji, et al., “Clinical Application of Transvenous Mitral Commissurotomy by a New Balloon Catheter,” The Journal of Thoracic and Cardiovascular Surgery 87:394-402, 1984.
International Search Report (dated Mar. 12, 2009), International Preliminary Report on Patentability (dated Mar. 30, 2010), and Written Opinion (dated Mar. 28, 2010), PCT/US2008/011188.
International Search Report and Written Opinion PCT/US2014/020872 dated Mar. 19, 2014.
International Search Report from corresponding PCT application No. PCT/US2011/054973 dated Apr. 23, 2012.
International Search Report PCT/US2009/004094 dated Mar. 3, 2010.
Knudsen, L.L. et al., “Catheter-implanted prosthetic heart valves,” The International Journal of Artificial Organs, May 1993, pp. 253-262, vol. 16, No. 5.
Kolata, Gina, “Device That Opens Clogged Arteries Gets a Failing Grade in a New Study,” nytimes.com, http://www.nytimes.com/1991/01/03/health/device-that-opens-clogged-arteri- es-gets-a-faili . . . , Jul. 29, 2009, 2 pages.
Lawrence, Jr., M.D., David D., “Percutaneous Endovascular Graft: Experimental Evaluation,” Radiology 1897; 163: 357-360.
Maribeth et al., Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks, Hourihan et al., Journal of the American College of Cardiology, vol. 20, No. 6, pp. 1371-1377, (1992).
Merriam Webster definition of “prevent,” www.merriam-webster.com/dictionary/prevent.
Merriam Webster definition of “retard,” www.merriam-webster.com/dictionary/retard.
Moazami, N. et al., “Transluminal Aortic Valve Placement,” ASAIO Journal, Sep./Oct. 1996, pp. M381-M385, vol. 42.
Muñoz, et al., “Guidance of treatment of perivalvular prosthetic leaks.”, Current cardiology reports, 16.430, 6 pages, Jan. 2014.
Pavcnik, M.D., Ph.D., Dusan, et al. “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Cardiovascular Radiology 1992; 183:151-154.
Porstmann, W., et al., “Der Verschlu.beta. des Ductus Arteriosus Persistens ohne Thorakotomie,” Thoraxchirurgie Vaskulare Chirurgie, Band 15, Heft 2, Stuttgart, im Apr. 1967, pp. 199-203, English translation of Abstract only.
Quaden, R. et al., “Percutaneous aortic valve replacement: resection before implantation,” European J. of Cardio-thoracic Surgery, May 2005, pp. 836-840, vol. 27, No. 5.
Rashkind, M.D., William J., “Creationof an Atrial Septal Defect Withoput Thoracotomy,” the Journal of the American Medical Association, vol. 196, No. 11, Jun. 13, 1966, pp. 173-174.
Rashkind, W. J., “Historical Aspects of Interventional Cardiology: Past, Present, Future,” Texas Heart Institute Journal, Dec. 1986, 13(4):363-367.
Rohde,et al., “Resection of Calcified Aortic Heart Leaflets In Vitro by Q-Switched 2 μm Microsecond Laser Radiation”, Journal of Cardiac Surgery, 30(2):157-62. Feb. 2015.
Rosch, M.D., Josef, “The Birth, Early Years and Future of Interventional Radiology,” J Vasc Interv Radiol 2003; 14:841-853.
Ross, F.R.C.S., D.N., “Aortic Valve Surgery,” Guy's Hospital, London, pp. 192-197, approximately 1968.
Ruiz, C., “Overview of PRE-CE Mark Transcatheter Aortic Valve Technologies,” Euro PCR, May 2010 (Powerpoint dated May 25, 2010).
Sabbah, A. N. et al., “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Dec. 1989, Journal of Cardiac Surgery, 4(4):302-309.
Selby, M.D., J. Bayne, “Experience with New Retrieval Forceps for Foreign Body Removal in the Vascular, Urinary, and Biliary Systems,” Radiology 1990; 176:535-538.
Serruys, P.W., et al., “Stenting of Coronary Arteries. Are we the Sorcerer's Apprentice?,” European Heart Journal (1989) 10, 774-782, pp. 37-45, Jun. 13, 1989.
Dewey, et al., “Transapical Aortic Valve Implantation: An Animal Feasibility Study”, The Annals of Thoracic Surgery, accepted for publication Feb. 2006, pp. 110-116, vol. 82, Elsevier, Inc.
Hijazi et al., “Transcatheter Valve Repair”, CRC Press, Jan. 2006, pp. 165-186.
Huber, et al., “Direct-Access Valve Replacement”, Journal of the American College of Cardiology, Jul. 2005, vol. 46, No. 2, Elsevier, Inc.
Lichtenstein et al., “Transapical Transcatheter Aortic Valve Implantation in Humans”, Circulation, published online Jul. 2006, pp. 591-596, vol. 114, American Heart Association, Dallas, TX, USA.
Lichtenstein, S.V., “Closed Heart Surgery: Back to the Future”, The Journal of Thoracic and Cardiovascular Surgery, May 2006, pp. 941-943, vol. 131, No. 5.
Mack, “Minimally invasive cardiac surgery”, Surgical Endoscopy, published online Mar. 23, 2006, pp. S488-S492, vol. 20.
Braido, et al., U.S. Appl. No. 29/375,260, filed Sep. 20, 2010, titled “Forked Ends”.
Walther, et al., “Transapical Approach for Sutureless Stent-Fixed Aortic Valve Implantation: Experimental Results”, European Journal of Cardio-Thoracic Surgery, May 2006, pp. 703-708, vol. 29, No. 5.
Webb et al., “Percutaneous Aortic Valve Implantation Retrograde From the Femoral Artery”, Circulation, published online Feb. 2006, pp. 842-850, vol. 113, American Heart Association, Dallas, TX, USA.
Related Publications (1)
Number Date Country
20200015963 A1 Jan 2020 US
Continuations (2)
Number Date Country
Parent 14688357 Apr 2015 US
Child 16545481 US
Parent 11906133 Sep 2007 US
Child 14688357 US